SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Deferred Income Tax
SCI Pharmtech Inc
Deferred Income Tax Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Deferred Income Tax | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Deferred Income Tax
NT$104.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
68%
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Deferred Income Tax
NT$468m
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
12%
|
|
![]() |
Formosa Laboratories Inc
TWSE:4746
|
Deferred Income Tax
NT$21m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
![]() |
ScinoPharm Taiwan Ltd
TWSE:1789
|
Deferred Income Tax
NT$1.3m
|
CAGR 3-Years
55%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-8%
|
|
![]() |
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Deferred Income Tax
NT$1.1B
|
CAGR 3-Years
53%
|
CAGR 5-Years
45%
|
CAGR 10-Years
10%
|
|
![]() |
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Deferred Income Tax
NT$85.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Deferred Income Tax?
Deferred Income Tax
104.5m
TWD
Based on the financial report for Dec 31, 2024, SCI Pharmtech Inc's Deferred Income Tax amounts to 104.5m TWD.
What is SCI Pharmtech Inc's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 10Y
68%
Over the last year, the Deferred Income Tax growth was -28%.